1. Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. (May 2021) Authors: Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Magalashvili, David; Sonis, Polina; Dolev, Mark; Menascu, Shay; Flechter, Shlomo; Falb, Rina; Gurevich, Michael Journal: Therapeutic advances in neurological disorders Issue: Volume 14(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Blood gene-expression profiling for preonset identification of multiple sclerosis. (September 2010) Authors: Achiron, Anat Journal: Future neurology Issue: Volume 5:Number 5(2010) Page Start: 629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brain Lesion Load and Anatomic Distribution in Patients With Juvenile Clinically Isolated Syndrome Predicts Rapidly Advanced to Multiple Sclerosis. (September 2018) Authors: Menascu, Shay; Legarda, Carolina; Miron, Shmuel; Achiron, Anat Journal: Journal of child neurology Issue: Volume 33:Number 10(2018:Oct.) Page Start: 633 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Central Neuropathic Pain in Multiple Sclerosis Is Associated with Impaired Innocuous Thermal Pathways and Neuronal Hyperexcitability. Issue 10 (18th March 2021) Authors: Rivel, Michal; Achiron, Anat; Dolev, Mark; Stern, Yael; Zeilig, Gabi; Defrin, Ruth Journal: Pain medicine Issue: Volume 22:Issue 10(2021) Page Start: 2311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients. Issue 1 (16th November 2020) Authors: Menascu, Shay; Khavkin, Yulia; Zilkha‐Falb, Rina; Dolev, Mark; Magalashvili, David; Achiron, Anat; Gurevich, Michael Journal: Annals of clinical and translational neurology Issue: Volume 8:Issue 1(2021) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients. Issue 1 (16th November 2020) Authors: Menascu, Shay; Khavkin, Yulia; Zilkha‐Falb, Rina; Dolev, Mark; Magalashvili, David; Achiron, Anat; Gurevich, Michael Journal: Annals of clinical and translational neurology Issue: Volume 8:Issue 1(2021) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cognitive functions and disability progression in relapsing-remitting multiple sclerosis: A longitudinal study. Issue 2 (4th March 2021) Authors: Heled, Eyal; Aloni, Roy; Achiron, Anat Journal: Applied neuropsychology Issue: Volume 28:Issue 2(2021) Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cognitive Performance of Patients With Multiple Sclerosis and Optic Neuritis at Presentation. Issue 1 (14th March 2022) Authors: Leshno, Ari; Sagiv, Oded; Aloni, Roy; Skaat, Alon; Achiron, Anat; Huna-Baron, Ruth Editors: Fraser, Clare; Mollan, Susan Journal: Journal of neuro-ophthalmology Issue: Volume 42:Issue 1(2022) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Cognitive Performance of Patients With Multiple Sclerosis and Optic Neuritis at Presentation. Issue 1 (March 2022) Authors: Leshno, Ari; Sagiv, Oded; Aloni, Roy; Skaat, Alon; Achiron, Anat; Huna-Baron, Ruth Other Names: Fraser Clare section editor.; Mollan Susan section editor. Journal: Journal of neuro-ophthalmology Issue: Volume 42:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022) Authors: Foley, John F; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan; van der Walt, Anneke; Dwyer, Christopher; Bu... Journal: Lancet neurology Issue: Volume 21:Issue 7(2022) Page Start: 608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗